Keryx Biopharmaceuticals to Present at the Bank of America 2008 Health Care Conference

Wednesday, May 14, 2008 General News J E 4
NEW YORK, May 13 Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairmanand Chief Executive Officer, is scheduled to present at the Bank of America2008 Health Care Conference in Las Vegas, Nevada

Mr. Weiss' presentation, which will take place on Thursday, May 15th at11:10am PT, will be webcast live and will be accessible from the InvestorInformation page of the Company's Website at Anarchived version of the webcast will be available following the conclusion ofthe live presentation.


Keryx Biopharmaceuticals is focused on the acquisition, development andcommercialization of medically important, novel pharmaceutical products forthe treatment of life-threatening diseases, including renal disease andcancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-basedcompound that has the capacity to bind to phosphate and form non-absorbablecomplexes. Zerenex is currently in Phase 2 clinical development for thetreatment of hyperphosphatemia (elevated phosphate levels) in patients withend-stage renal disease, or ESRD. The Company is also developing KRX-0401(perifosine), a novel, potentially first-in-class, oral anti-cancer agent thatmodulates Akt, a protein in the body associated with tumor survival andgrowth. KRX-0401 also modulates a number of other key signal transductionpathways, including the JNK and MAPK pathways, which are pathways associatedwith programmed cell death, cell growth, cell differentiation and cellsurvival. KRX-0401 is currently in Phase 2 clinical development for multipletumor types. The Company also has an in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. Keryx isheadquartered in New York City.KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail:

SOURCE Keryx Biopharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Delcath To Present at the Rodman & Renshaw 5th Ann...
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagu...